Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
…, HM Kantarjian, J Cortes, M Beran, CA Koller… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: To assess the efficacy of combination therapy with fludarabine and cyclophosphamide
in patients with chronic lymphocytic leukemia (CLL) based on data suggesting in vitro …
in patients with chronic lymphocytic leukemia (CLL) based on data suggesting in vitro …
The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia
…, FJ Giles, A Dey, Z Estrov, CA Koller… - Blood, The Journal …, 2002 - ashpublications.org
Tumor necrosis factor-α (TNF-α), a cytokine possessing pleiotropic biological activities, is
produced by leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL) and …
produced by leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL) and …
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
…, J Cortes, FJ Giles, WG Wierda, CA Koller… - Cancer, 2003 - Wiley Online Library
BACKGROUND The objective of this study was to investigate the efficacy and safety of
alemtuzumab, the humanized anti‐CD52 monoclonal antibody, in patients with B‐cell chronic …
alemtuzumab, the humanized anti‐CD52 monoclonal antibody, in patients with B‐cell chronic …
[HTML][HTML] Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia
…, J Cortes, D Thomas, CA Koller… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Purpose The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse;
some patients have indolent disease, never needing treatment, whereas others have …
some patients have indolent disease, never needing treatment, whereas others have …
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
…, MB Rios, FJ Giles, M Beran, CA Koller… - … Journal of the …, 1999 - Wiley Online Library
BACKGROUND The prognoses of patients with chronic myelogenous leukemia in blastic
phase (CML‐BP) are extremely poor. Treatment of patients with nonlymphoid CML‐BP is …
phase (CML‐BP) are extremely poor. Treatment of patients with nonlymphoid CML‐BP is …
Eradication of minimal residual disease in hairy cell leukemia
…, JL Jorgensen, SM O'Brien, S Verstovsek, CA Koller… - Blood, 2006 - ashpublications.org
Although the nucleoside analogs cladribine and pentostatin produce high response rates in
patients with hairy cell leukemia (HCL), a significant number of patients eventually relapse. …
patients with hairy cell leukemia (HCL), a significant number of patients eventually relapse. …
High‐dose chemotherapy in high‐risk myelodysplastic syndrome: Covariate‐adjusted comparison of five regimens
M Beran, Y Shen, H Kantarjian, S O'Brien, CA Koller… - Cancer, 2001 - Wiley Online Library
BACKGROUND Antileukemic chemotherapy has been used for two decades to treat high‐risk
myelodysplastic syndrome (refractory anemia with excess of blasts [RAEB] and RAEB in …
myelodysplastic syndrome (refractory anemia with excess of blasts [RAEB] and RAEB in …
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
…, E Estey, S O'Brien, J Cortes, CA Koller… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: To evaluate the efficacy and safety of the combination of topotecan and
cytarabine in patients with myelodysplastic syndromes (MDSs) and chronic myelomonocytic …
cytarabine in patients with myelodysplastic syndromes (MDSs) and chronic myelomonocytic …
Combination therapy with arsenic trioxide, all‐trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
…, HM Kantarjian, EH Estey, CA Koller… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND. From 20% to 30% of patients with acute promyelocytic leukemia (APL) who
are treated with all‐trans retinoic acid (ATRA) develop recurrent disease. Arsenic trioxide (…
are treated with all‐trans retinoic acid (ATRA) develop recurrent disease. Arsenic trioxide (…
The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia
CA Koller, HM Kantarjian, D Thomas, S O'Brien… - Leukemia, 1997 - nature.com
Sixty-six adults with refractory acute lymphocytic leukemia received salvage therapy with
the ‘hyper-CVAD’regimen, consisting of eight courses of alternating intensive chemotherapy …
the ‘hyper-CVAD’regimen, consisting of eight courses of alternating intensive chemotherapy …